The report is available in English with a French summary - KCE

More documents

Recommendations

Info

88 Plasma KCE Reports 120 The proportion of acute ITP that had evolved into chronic ITP was estimated in four studies in Norway, France, Denmark and Nordic countries in 1996-99 and ranged 18- 33% (average 26%). 155, 156,157,158 We then extrapolated the incidence rate of chronic ITP at 0.8 per 100,000 in children
KCE Reports 120 Plasma 89 In Belgium, a survey covering 6 centres for paediatric PID and 3 centres for adult PID reported a total of 437 PID cases under follow up, but this figure is also incomplete. Among these, 263 have received IG treatment in 2008. In order to estimate the total number of PID cases treated in Belgium, we have used as proxy the proportion of all Belgian bone marrow transplants that were conducted in these centres, as reported to the INAMI/RIZIV. Though the proportion of transplants is not directly linked to the proportion of PID treated, this was considered as a proxy of specialized immunological activity of these centres. The 6 centres providing data on paediatric cases and the 3 centres providing data on adult cases represent respectively 34% and 29% of all marrow transplants in 2007. The number of PID cases under treatment is thus estimated at 806 cases. In Belgian centres surveyed, the dosage ranged 0.3-0.5g/kg and most centres used 0.4g/kg. The annual number of IVIG treatment per year ranged 6.4-14.4 per year for children (average 11.3) and 12.0-13.3 per year for adults (average 11.8). The amount of IG required for SC administration has been estimated as equivalent to those required for IV administration. Multiple myeloma (MM) In Belgium, a range of 617-690 new cases of MM were reported per year to the cancer registry in 2004-2008 and the incidence is increasing with age. Prevalence data are not available from Belgium or other EU countries. We used the 2006 age-specific prevalence rates reported among the white population in the US and extrapolated to the Belgian population by age-group. 8 A number of 2390 prevalent cases of MM are estimated. This figure may be an underestimation of the Belgian situation because the MM incidence rates in the US are slightly lower than the Belgian incidence rates. The proportion of MM patients treated was not documented in the literature, but expert advice provided a range of 10-15%, based on experience. The survey among immuno-haematologists collected data on MM from one Belgian university hospital only. The dosage of 0.4g/kg was similar to the recommendations of other countries and in average 10 treatments were provided per case and year. Chronic lymphocytic leukaemia (CLL) National data are not available on the incidence or prevalence of CLL but 636 new cases of lymphoid leukaemia (acute and chronic) were reported in 2008. No prevalence data were found from other countries. The proportion of patients treated was also not available. As for MM, the survey among immuno-haematologists collected data on MM from one Belgian university hospital only. The dosage was 0.4g/kg and an average of 10 treatments was provided per case and year. Due to the lack of data, IG amounts required to treat CLL cases could not be calculated. Allogenous bone marrow or stem cell transplant (SCT) The number of bone marrow transplants is collected by the INAMI/RIZIV in the framework of the convention with transplant centres. In 2007, 284 allogenous transplants were recorded, and the 2005-07 data show a gradual increase in the number of allogenous SCT (+31% in 2 years). The number of transplant was then estimated at 320 for 2008, assuming a linear trend from 2005 to 2007. However, this number may be underestimated as hospitals that are not included in the Convention may also perform allogenous SCT (INAMI, personal communication). 8 Estimated US cancer prevalence counts at on Jan 1, 2006 by Race/Ethnicity, Sex and Years Since Diagnosis. National Cancer Institute: Surveillance Epidemiology and End Results Cancer Statistics Review 1975 – 2006. http://seer.cancer.gov/csr/1975_2006/browse_csr.php?section=18&page=sect_18_table.18.html
Page 1 and 2:
Comment assurer l’autosuffisance
Page 3 and 4:
Comment assurer l’autosuffisance
Page 5 and 6:
KCE Reports 120B Plasma i PRÉFACE
Page 7 and 8:
KCE Reports 120B Plasma iii MÉTHOD
Page 9 and 10:
KCE Reports 120B Plasma v En ce qui
Page 11 and 12:
KCE Reports 120B Plasma vii RECOMMA
Page 13 and 14:
KCE Reports 120 Plasma 1 Scientific
Page 15 and 16:
KCE Reports 120 Plasma 3 GLOSSARY A
Page 17 and 18:
KCE Reports 120 Plasma 5 1 INTRODUC
Page 19 and 20:
KCE Reports 120 Plasma 7 Focus: sta
Page 21 and 22:
KCE Reports 120 Plasma 9 Two techni
Page 23 and 24:
KCE Reports 120 Plasma 11 Therefore
Page 25 and 26:
KCE Reports 120 Plasma 13 FRENCH-SP
Page 27 and 28:
KCE Reports 120 Plasma 15 Number of
Page 29 and 30:
KCE Reports 120 Plasma 17 Table 4:
Page 31 and 32:
Page 33 and 34:
Page 35 and 36:
KCE Reports 120 Plasma 23 Role of t
Page 37 and 38:
KCE Reports 120 Plasma 25 2.1.3.2 P
Page 39 and 40:
KCE Reports 120 Plasma 27 • 73% o
Page 41 and 42:
KCE Reports 120 Plasma 29 2.2 TRANS
Page 43 and 44:
KCE Reports 120 Plasma 31 Figure 6:
Page 45 and 46:
KCE Reports 120 Plasma 33 GEOGRAPHI
Page 47 and 48:
KCE Reports 120 Plasma 35 It is sur
Page 49 and 50: KCE Reports 120 Plasma 37 Plasma fr
Page 51 and 52: KCE Reports 120 Plasma 39 2.3 LIMIT
Page 53 and 54: KCE Reports 120 Plasma 41 Table 17:
Page 55 and 56: KCE Reports 120 Plasma 43 3.2 INDIC
Page 57 and 58: KCE Reports 120 Plasma 45 Subcutane
Page 61 and 62: KCE Reports 120 Plasma 49 3.2.2 Evi
Page 63 and 64: KCE Reports 120 Plasma 51 Search re
Page 65 and 66: KCE Reports 120 Plasma 53 CIDP IG i
Page 67 and 68: KCE Reports 120 Plasma 55 • IG re
Page 69 and 70: KCE Reports 120 Plasma 57 Solid org
Page 71 and 72: KCE Reports 120 Plasma 59 A Cochran
Page 73 and 74: KCE Reports 120 Plasma 61 • In ch
Page 75 and 76: KCE Reports 120 Plasma 63 Two small
Page 77 and 78: KCE Reports 120 Plasma 65 was lower
Page 79 and 80: KCE Reports 120 Plasma 67 Three RCT
Page 81 and 82: KCE Reports 120 Plasma 69 Severe se
Page 83 and 84: KCE Reports 120 Plasma 71 The analy
Page 85 and 86: KCE Reports 120 Plasma 73 3.3.1.2 T
Page 87 and 88: KCE Reports 120 Plasma 75 Figure 7:
Page 89 and 90: KCE Reports 120 Plasma 77 Figure 10
Page 95 and 96: KCE Reports 120 Plasma 83 • For b
Page 97 and 98: KCE Reports 120 Plasma 85 3.3.2.6 L
Page 99: KCE Reports 120 Plasma 87 • The p
Page 103 and 104: KCE Reports 120 Plasma 91 Multifoca
Page 105 and 106: KCE Reports 120 Plasma 93 Based on
Page 107 and 108: KCE Reports 120 Plasma 95 Disease /
Page 109 and 110: KCE Reports 120 Plasma 97 3.3.4 Exp
Page 111 and 112: KCE Reports 120 Plasma 99 Figure 12
Page 113 and 114: KCE Reports 120 Plasma 101 Key poin
Page 115 and 116: KCE Reports 120 Plasma 103 Key poin
Page 117 and 118: KCE Reports 120 Plasma 105 • Conf
Page 119 and 120: KCE Reports 120 Plasma 107 As far a
Page 121 and 122: KCE Reports 120 Plasma 109 Followin
Page 123 and 124: KCE Reports 120 Plasma 111 4.3 HOW
Page 125 and 126: KCE Reports 120 Plasma 113 Improvin
Page 127 and 128: KCE Reports 120 Plasma 115 4.3.2 St
Page 129 and 130: KCE Reports 120 Plasma 117 4.4 CONC
Page 131 and 132: KCE Reports 120 Plasma 119 FAVOURIN
Page 133 and 134: KCE Reports 120 Plasma 121 APPENDIX
Page 135 and 136: KCE Reports 120 Plasma 123 For othe
Page 137 and 138: KCE Reports 120 Plasma 125 Table 48
Page 143 and 144: KCE Reports 120 Plasma 131 Distribu
Page 145 and 146: KCE Reports 120 Plasma 133 • Conv
Page 149 and 150: KCE Reports 120 Plasma 137 6 REFERE
Page 151 and 152:
KCE Reports 120 Plasma 139 41. Pruz
Page 153 and 154:
KCE Reports 120 Plasma 141 82. Comi
Page 155 and 156:
KCE Reports 120 Plasma 143 123. Cre
Page 157 and 158:
KCE Reports 120 Plasma 145 165. Cua
Page 159 and 160:
This page is left intentionally bla
Page 161 and 162:
KCE reports 1. Efficacité et renta
Page 163 and 164:
73. Financement du programme de soi
show all

The report is available in English with a French summary - KCE

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?